Supplementary Figure 7 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Nilotpal Roy(Symbiosis International University), Matthew P. Patricelli(Vividion Therapeutics (United States)), Robert T. Abraham(Sanford Burnham Prebys Medical Discovery Institute), Dhaval P. Bhatt(Washington University in St. Louis), Eric M. Walton(Vividion Therapeutics (United States)), Ilah Bok(University of South Florida), Géza Ambrus-Aikelin(Genesis Medical Center), Khoi Le(Vividion Therapeutics (United States)), Kenneth Hee(IDEXX Laboratories (France)), Christie L. Eissler(Vividion Therapeutics (United States)), Emily Wilkerson(Washington University in St. Louis), Noah Ibrahim(Vividion Therapeutics (United States)), Todd M. Kinsella(Vividion Therapeutics (United States)), Aaron N. Snead(Vividion Therapeutics (United States)), Benjamin D. Horning(Princeton University), Jordon M. Inloes(Vividion Therapeutics (United States)), Brent M. Kuenzi(Vividion Therapeutics (United States)), Steffen M. Bernard(Vividion Therapeutics (United States)), Aulma R. Parker(Vividion Therapeutics (United States)), I‐Chung Lo(Precision Therapeutics (United States)), Harit Panda(Washington University in St. Louis), David S. Weinstein(National Bureau of Economic Research), Stephanie Grabow(Dana-Farber Cancer Institute), Tine Wyseure(Scripps Research Institute), G Simon(Vividion Therapeutics (United States)), Kathleen R. Negri(Vividion Therapeutics (United States)), Paul Zolkind(Washington University in St. Louis), Marie Pariollaud(Scripps Research Institute), Justine Lu(Vividion Therapeutics (United States)), Joseph S. McLaughlin(Vividion Therapeutics (United States)), Jonathan Pollock(Vividion Therapeutics (United States)), Zoe Rush(Vividion Therapeutics (United States)), Eileen Tran(Vividion Therapeutics (United States)), U‐Ging Lo(Vividion Therapeutics (United States)), Heather N. Williams(Vividion Therapeutics (United States)), S. Saeidi(Washington University in St. Louis), Martha K. Pastuszka(Vividion Therapeutics (United States)), J. Sigler(Vividion Therapeutics (United States)), Jason C. Green(Vividion Therapeutics (United States)), Sarah Jacinto(Vividion Therapeutics (United States)), Michael B. Major(Washington University in St. Louis)
Cited by 0
Related Papers
Guidelines for the use and interpretation of assays for monitoring autophagy
|Autophagy|2012|4.1k
Cell cycle checkpoint signaling through the ATM and ATR kinases
|Genes & Development|2001|2k
A role for ATR in the DNA damage-induced phosphorylation of p53
|Genes & Development|1999|1k
Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 IsMediated by p70S6 Kinase
|Journal of Biological Chemistry|2005|557
An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action
|Nature Medicine|2014|463